Top of page
Health

Researchers discover how a top-ranking risk gene for autism causes seizures

Creative background, dna structure, dna molecule on a blue background

University at Buffalo researchers have revealed the biological mechanisms behind a key risk gene that plays a role in a number of brain diseases, including autism spectrum disorder (ASD). They have also discovered a method of potentially rescuing some of the comorbidities that this risk gene causes.

The preclinical research, published this week in Nature Communications, focuses on a gene known as ASH1L. Large-scale human genetic studies have identified ASH1L as a high-risk gene for ASD, and conditions that sometimes accompany it, such as epilepsy, Tourette syndrome and intellectual disability.

But exactly how the loss of function of ASH1L contributes to all of these diseases with overlapping symptoms has remained largely unknown.

Led by Zhen Yan, Ph.D., senior author and SUNY Distinguished Professor in the Department of Physiology and Biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB, the team was motivated to do the study after its initial finding that ASH1L expression is significantly decreased in the prefrontal cortex (PFC) of postmortem tissues from ASD patients. The prefrontal cortex is the part of the brain responsible for executive function, such as cognitive processes and emotional control.

The UB researchers found that in mice with ASH1L deficiency in the PFC, synaptic genes, which are responsible for ensuring proper information processing in the brain, are downregulated. This causes the imbalance of signals mediated by the major excitatory and inhibitory neurotransmitters in the nervous system: respectively, glutamate and Gamma-aminobutyric acid (GABA). Normal brain functioning depends on precise regulation of glutamate and GABA levels in the brain.

At the same time, these mice demonstrated hyperexcitability of glutamatergic neurons in the prefrontal cortex, which induced severe seizures and early mortality.

Through an approach they describe as chemogenetic, the UB researchers were able to restore the excitation/inhibition balance among neurons, reducing seizures and prolonging survival of the mice with ASH1L deficiency.

However, they found that the social deficits and repetitive behaviors in these animals persisted. They plan to continue to study other methods that might result in overcoming these negative effects.

“These results have revealed the critical role of a top-ranking autism spectrum disorder risk factor in regulating synaptic gene expression and seizures, which provides insights into treatment strategies for related brain diseases,” said Yan.

You might also like

Close up portrait of two disabled twin sisters laughing outdoors. Close up portrait of two disabled twin sisters laughing outdoors.

New Intellectual Disability Health Service launches in Adelaide

South Australians with intellectual disabilities are set to have improved…

Boy during sensory integration therapy Boy during sensory integration therapy

ESSA launches eBook promoting movement for Aussies with disabilities

Exercise and Sports Science Australia (ESSA) is marking International Day…

Alzheimer's Patient Alzheimer's Patient

Scientists discover potential cause of Alzheimer’s Disease

Prevailing theories posit plaques in the brain cause Alzheimer’s disease.…

Close-up portrait of senior woman with dementia who is looking through window. Close-up portrait of senior woman with dementia who is looking through window.

Memory Clinic Guidelines released to support dementia diagnosis

A UNSW Sydney Centre for Healthy Brain Ageing (CHeBA) collaboration with the…